U.S., July 4 -- ClinicalTrials.gov registry received information related to the study (NCT07050472) titled 'Durvalumab After Concurrent Chemoradiotherapy (cCRT) for Limited-stage Small-cell Lung Cancer (LS-SCLC)' on June 12.
Brief Summary: This is a retrospective, single-center study evaluating the effectiveness and safety of consolidative durvalumab after cCRT in LS-SCLC in real-world setting.
Study Start Date: July, 2025
Study Type: OBSERVATIONAL
Condition:
Small-cell Lung Cancer
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Anhui Shi, MD
Information provided by (Responsible Party): Anhui Shi, MD, Peking University Cancer Hospital & Institute
Published by HT Digital Content Services with permission from Health Daily Digest....